according to the American Cancer Society. GSK’s acquisition of IDRx will include IDRX-42 which is currently being developed and trialled as therapy for the treatment of gastrointestinal stomal ...
Evening Standard on MSN16d
GSK buys US-based rare cancer treatment developer for up to £1bnThe acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback